Stocks To Buy 2017 | Pharma

While 2017 was a banner year, several headwinds shaped investment strategies: Pharm Exec's Top 50 Companies 2017 | PharmExec

: Soared over 440% after announcing a gene therapy partnership with Pfizer . pharma stocks to buy 2017

: Delivered a 516% return as it dominated its niche in the metabolic disease market. While 2017 was a banner year, several headwinds

: Led the industry in R&D spending, focused heavily on its blockbuster immunotherapy Keytruda . While 2017 was a banner year

: Rose nearly 700% following a lucrative licensing deal with Novartis for its antibody gevokizumab.